David A. Jans

24.4k citations
369 papers · 19.5k indexed · 3 hit papers · h-index 75

Impact in

  • Virology top 0.2%
    • HIV Research and Treatment
    • Viral Infections and Vectors
    • SARS-CoV-2 and COVID-19 Research

Papers in

David A. Jans

365 papers receiving 19.1k citations

Hit Papers

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro 2020 · 1.5k citations
1.5k20122026201620214008001.2k

Peers

David A. Jans
Comparison fields: 5 of 160
  • Virology 1.7k
  • Infectious Diseases 4.6k
  • Molecular Biology 11.3k
  • Genetics 3.0k
  • Parasitology 611
Replace Yoshiharu Matsuura with:
Yoshiharu Matsuura Japan
Naoki Yamamoto Japan
Dennis A. Carson United States
Jae U. Jung United States
Richard S. Blumberg United States
Robert I. Lehrer United States
Stephen H. Leppla United States
Judy Lieberman United States
Judith M. White United States
Marie‐Christine Prévost France
David A. Jans relative to Yoshiharu Matsuura Japan Yoshiharu Matsuura's profile →
Citations per field
00.5×1.5×1.9×
Yoshiharu Matsuura · 1×
Citations per year

Countries citing papers authored by David A. Jans

Since Specialization
Citations

This map shows the geographic impact of David A. Jans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Jans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Jans more than expected).

Fields of papers citing papers by David A. Jans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Jans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Jans. The network helps show where David A. Jans may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David A. Jans, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Jans Line = papers co-authored together David A. Jans links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20243
3 20237
4 202110
5 202127
6 2016155
7 20168
8 201516
9 201311
10 20121
11 201132
12 201159
13 200643
14 200514
15 2003170
16 200335
17 200215
18 2000451
19 19988
20
Semi-intact cells for nucleo-cytoplasmic transport studies
19943

About David A. Jans

David A. Jans is a scholar working on Virology, Infectious Diseases, Molecular Biology, Genetics and Animal Science and Zoology, having authored 369 papers that have together received 19.5k indexed citations. Recurring topics across this work include Nuclear Structure and Function (136 papers), RNA Research and Splicing (86 papers), HIV Research and Treatment (45 papers), Virus-based gene therapy research (43 papers), Genomics and Chromatin Dynamics (41 papers), Mosquito-borne diseases and control (38 papers), RNA Interference and Gene Delivery (36 papers) and Viral Infections and Vectors (29 papers). The work is most often cited by research in Virology (1.7k citations), Infectious Diseases (4.6k citations), Molecular Biology (11.3k citations), Genetics (3.0k citations) and Parasitology (611 citations). David A. Jans has collaborated with scholars based in Australia, United States and Germany. Frequent co-authors include Kylie M. Wagstaff, Stefan Hübner, Leon Caly, Chong-Yun Xiao, Mike Catton, Julian Druce, Mark H.C. Lam, Dominic J. Glover, Patricia Jans and Lyndall J. Briggs. Their work appears in journals such as Journal of Biological Chemistry, Biochemical Journal, Journal of Virology, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026